The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Utilizing midkines to improve outcomes in SCLC and MCC
Curtis Perry, MD, PhD, Yale University, New Haven, CT, describes the benefits of identifying midkines in immune resistant Merkel cell carcinoma (MCC) and small cell lung cancer (SCLC) tumors, highlighting the possibility of improved patient outcomes through enhanced treatment strategies. Dr Perry emphasizes the importance of personalized medicine and the need for further research to fully understand the mechanisms underlying these cancers. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We’re really hopeful that both midkines specifically, but also most likely many other different therapies and interventions are going to be required to deal with patients whose tumors find a way to be resistant to immunotherapy. So we really want to be able to use not only midkines but also this platform to really be able to study novel therapies as we continue to advance and really try to be able to bring therapies forward more efficiently, safer to patients who need them...
We’re really hopeful that both midkines specifically, but also most likely many other different therapies and interventions are going to be required to deal with patients whose tumors find a way to be resistant to immunotherapy. So we really want to be able to use not only midkines but also this platform to really be able to study novel therapies as we continue to advance and really try to be able to bring therapies forward more efficiently, safer to patients who need them. Thank you.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Research Funding – AstraZeneca (Inst)
